Trump Media and Technology Group Corp vs Heron Therapeutics Inc — how do they compare? Trump Media and Technology Group Corp trades at $8.12 (market cap $2.28B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Trump Media and Technology Group Corp is far larger — about 33.5× Heron Therapeutics Inc's market cap, and Trump Media and Technology Group Corp is more actively traded (3,148,379 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Heron Therapeutics Inc for 35 Days on average.
| DJT | HRTX | |
|---|---|---|
Market Cap | $2.28B | $68.01M |
Volume | 3,148,379 | 1,891,941 |
Sector | Media | Health |
52-Week High | $17.07 | $1.49 |
52-Week Low | $7.06 | $0.27 |
Typical Hold Time | 17 Days | 35 Days |
Enterprise Value | $2.35B | $174.75M |
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.125, down 1.16% with a bearish technical signal. The company shows minimal revenue of $3.68M against massive losses of -$712M, resulting in a negative net margin of -28,860%. Cash flow trends reveal heavy investing outflows, while a proposed merger with TAE Technologies aims to pivot toward fusion energy development. The stock faces significant fundamental challenges despite oversold RSI indicators.
Outlook remains highly speculative with substantial execution risks. The merger could provide long-term upside if fusion technology commercializes, but current financials and negative profitability signal extreme caution. Investors face dilution risk and cash burn with no near-term profit visibility.
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →